Introduction {#sec1}
============

Biomedical databases support many aspects of biological research, from getting basic information about a gene or a protein, to complex applications for data analysis. The usefulness of these databases critically depends on the amount of information, its correct interpretation and the regular updating of the content. For the vast majority of databases, these curatorial tasks are done manually by curators with expertise in the specific domain of interest of the database. To give an appreciation of the scope of the task, the volume of biomedical literature in PubMed, a free literature search service developed and maintained by the National Center for Biotechnology Information, currently containing 28 million citations, has increased at a sustained growth rate of ∼4% over the past 20 years ([@ref1]).

It has been stated repeatedly that manual curation is inadequate to keep up with the volume of information published (for example in ([@ref2])). Meanwhile, no fully automated tools have been successfully implemented in the annotation workflow of major databases. The essential features required for a complete or at least partial replacement of manual curation include accurate prioritization of the literature to serve database-specific curation tasks, correct detection of bioentities (named-entity recognition) as well as recall and precision rates approaching manual curation. Moreover, since best practices in curated databases require the assignment of unique identifiers to entities derived from biomedical ontologies, automated tools should be able to convert natural language into these controlled languages. Tools able to perform those tasks can be used to perform literature triage, bioentity identification and normalization, relationship extraction \[typically between a gene product and a disease (D) or a biological process (BP), for instance\] and association of supporting evidence qualifiers ([@ref3]). These tools would facilitate and accelerate the curation process, hence improving its cost-effectiveness and throughput.

The ideal tool for retrieving biomedical information would display a user-friendly interface, provide a powerful search tool from databases containing up-to-date biomedical data, allow a search within specific sections of articles, highlight terms of interest, display results that could be filtered and ranked, create annotations and respond fast following the request. Existing text-mining tools exhibit some of these features but none have all the required functionality, as we show in our analysis of currently available text-mining-supported curation tools ([Table 1](#TB2){ref-type="table"}). We assessed Textpresso Central ([@ref4]), PubMed ([@ref5]), NextBio, PolySearch ([@ref6]), GoPubMed ([@ref7]) and PubTator ([@ref8]) and evaluated all parameter listed in [Table 1](#TB2){ref-type="table"}. We also looked at the workflow of other text-mining tools, such as Argo ([@ref9]), Egas ([@ref13]), EXTRACT ([@ref14]), MetastasisWay ([@ref15]), Ontogene ([@ref16]) and RegulonDB ([@ref17]), but because they are dedicated to specific biomedical fields (and not appropriate for our use cases), we didn't include them in our comparative study. The functionalities important to the curation workflow must be close in quality to that of manual annotation. However, direct comparison is not always possible as automatic systems exhibit characteristics that do not align one-to-one with curation tasks as performed by humans. More importantly, the digitalization of curation workflows may require to challenge existing end-users' practices and well-established workflows ([@ref18]); data stewardship and capture need revision in order to also keep track of materials rejected by biocurators (wrong annotations, irrelevant articles etc.). Nevertheless, for the annotations proposed by the system, a precision of 60--70% seems a minimal---yet demanding---target to meet the curators' expectations. Similar quantitative targets also apply to triage tasks. Considering that a 100% manual triage is not achievable, any improvement over existing tools is welcome. Indeed, triage tasks are a bottleneck and cannot be performed without using general-purpose search engines such as PubMed or Europe PubMedCentral (PMC).

###### 

Comparison of some existing text-mining tools

  --
  --

The performance of the main parameters important for the curation workflow is indicated by the degree of shading: white means feature not available; light grey, medium performance; and dark gray, very good performance.

neXtProt ([@ref19]) is a knowledgebase focused on human proteins, which complements UniProtKB ([@ref20]) by extending the content and tools, supporting use cases specifically relevant to human proteins. neXtProt manually annotates various aspects of protein function, variants and phenotypes ([@ref19], [@ref21]). To do this, we have developed a curation tool, the BioEditor, that allows curators to capture biomedical data. Annotations are structured in triplets, in accordance with the neXtProt BioEditor annotation data model. The triplets are composed of a subject (the protein being annotated); an object describing a gene ontology (GO) term, a D, an interaction partner etc.; and a relation describing how the subject and the object are related.

We have developed an automatic article-processing tool that addresses our specific curation needs, neXtA~5~ ([@ref22], [@ref23]). neXtA~5~ provides a search engine coupled with an annotation system, directly integrated into the workflow of curators. Thus, neXtA~5~ assists curation with specific modules optimized for the various curation tasks: document triage, entity annotation and relationship extraction. The tool performs literature retrieval and prioritization and creates annotations. The curator queries the system by entering a human gene name and an axis of interest. For the purposes of this study, two axes were evaluated: GO BP as well as Ds. The system returns a ranked list of abstracts and concepts for the relevant axis for each of the papers. The curator can select the relevant articles/gene/concept combination and validate/refine/reject annotations proposed by the system.

In previous work, we have optimized the ranking algorithm of neXtA~5~ for the triage task. The tool exhibits significant improvements of 191--261% compared to PubMed ([@ref22], [@ref23]). The present article describes the testing and evaluation of neXtA~5~ by expert curators. To evaluate the accuracy and performance of neXtA~5~, we submitted specific requests and then compared the results obtained from manual curation to the results given by the neXtA~5~ application. The analysis is focused on the usability of neXtA~5~ on two types of annotations: BPs and Ds, respectively defined as GO concepts ([@ref24], [@ref25]) and National Cancer Institute thesaurus ([https://ncit.nci.nih.gov/](https://ncit.nci.nih.gov/))). We have evaluated the relevance of the papers proposed as well as the recall and precision of the concepts extracted.

Methods and results {#sec2}
===================

neXtA~5~ software infrastructure {#sec3}
--------------------------------

The neXtA~5~ system was developed with Java/JavaScript technologies to improve the scientific literature curation process as it is currently performed with neXtProt.

### Publication retrieval and concept extraction {#sec4}

SIB Text Mining houses the complete MEDLINE collection locally, updated on a weekly basis, in an information system named BioMed, that pre-indexes the collection using the Terrier and ElasticSearch platforms ([@ref26], [@ref23]) according to vocabularies relevant to the axes of interest. Again, here we focused on GO BP and Ds. BioMed services support the maintaining of several premier molecular biology databases, including Europe PMC's SciLite or UniProt's UPCLASS ([@ref27]). Indexed papers are analyzed and concepts from the ontology of interest are extracted and stored in the BioMed database, as well as human gene names obtained from the neXtProt application programming interface (API). Once the information is stored, BioMed applies a combination of weighting schemas, which includes a vector space model representation ([@ref30]), and the Okapi BM25 scoring function, which was tuned and tested during Text Retrieval Conference (TREC) competitions ([@ref31]). This results in two outputs: (i) a ranked list of abstracts and (ii) for each abstract, a ranked list of concepts for the axis of interest. The ranking function is described in a previous publication ([@ref22]).

### Document prioritization {#sec5}

The list of documents provided by the search engine is further ranked with a score based on a linear combination of factors; each of the search axis was tuned specifically to fit the curation model of neXtProt curators as detailed in ([@ref22], [@ref23]). This final score is calculated on the basis of the search engine score, combined with the range of concepts found in the paper and the term frequency--inverse document frequency (TF--IDF).

![Activity diagram of the literature curation process using neXtA~5~.](bay129f1){#f1}

### User interface {#sec6}

We have implemented a web-based curation interface that connects the BioEditor curation database with a set of APIs. The first screen is dedicated to the user input, with customized intake fields to refine the original query. The second panel displays the result of the triage function, with the final score granted to each document. Finally, in a third screen, a list of automatically generated annotations is proposed for each document. Each entry can be accepted as it stands, rejected or modified as needed. At the end, the curator can submit the annotation to the BioEditor. The work can also be saved at any time and completed subsequently. Indeed, the graphical user interface (GUI) is also linked to a historical database that keeps track of the curation process and results, which can also serve to set out a relevance feedback. This history enables the system to remember every processed publication and remove them from upcoming searches (using the same query).

neXtA~5~ user interface {#sec7}
-----------------------

The workflow of the neXtA~5~ curation-support tool is shown in [Figure 1](#f1){ref-type="fig"}.

The neXtA~5~ user interface is designed to assist specific biocuration tasks ([Figure 2](#f2){ref-type="fig"}). The user performs a query, which is a gene name and an annotation axis. Additional features include the ability for users to exclude specific references that will not be retrieved by the system (e.g. publications that were previously processed or publications of low interest). Users can also provide keywords that must be 'excluded', for instance because they result in too many false positives, or 'added', in which case they will receive more weight during the ranking step, for the ranking. Finally, advanced options allow the user to restrict the search based on a range of publication dates, the maximum number of publications to retrieve.

![neXtA~5~ user interface for query page.](bay129f2){#f2}

The output of the query is a list of publications, ranked according to the relevance score developed in ([@ref22]). The list displays relevant information about the publication, including the PMID, the title, the year of publication, the relevance score and the annotation status. Different annotation statuses are possible: 'not done', 'partial' (when some but not all the annotations proposed by the system have been reviewed by the curator) or 'completed' (when every automatic annotation has been manually reviewed).

From this ranked list, the curator can select a paper to curate that opens another page in the user interface displaying the list of potential annotations identified by neXtA~5~. The potential annotations are presented in table form, showing the subject (which corresponds to the protein of interest), the relation, the object (concept) and the evidence code (Eco). For each annotation, when the user clicks on the 'Show' button (in the 'Details' column on the right), the abstract appears, highlighting the sentence from which the annotation was derived in blue and underlining the concept ([Figure 3](#f3){ref-type="fig"}). Here, three operations are possible, from a pull-down menu in the 'Action' column; the curator can accept, modify or reject the annotations created by neXtA~5~. The curator can also change the relation linking subject and object as well as the Eco (currently these are set to default values in the interface); however, changes in the relation or the Eco does not impact the type of action; if the concept was not changed, then the annotation is considered as 'accepted'.

![neXtA~5~ user interface for curation. From the abstract of an article, neXtA~5~ extracts relevant concepts and displays a list of potential annotations. Here, the annotations related to PIM1 for the BPs and extracted from the abstract of ([@ref32]) are shown.](bay129f3){#f3}

neXtA~5~ usability study {#sec8}
------------------------

To evaluate the usability of neXtA~5~ as a curation support system, we measured the recall and precision of the annotations proposed by the system as compared to manual curation. The precision corresponds to the fraction of relevant instances among the retrieved instances, while recall is the fraction of relevant instances that have been retrieved over the total number of relevant instances. Here, 'instances' can correspond to either documents or concepts.

Four experienced curators from the neXtProt team reviewed the neXtA~5~ output. The evaluation focused on neXtA~5~ annotation for 12 different proteins: CDK2 (NX_P24941), CSK (NX_P41240), FYN (NX_P06241), IRAK4 (NX_Q9NWZ3), LRRK2 (NX_Q5S007), LYN (NX_P07948), PIM1 (NX_P11309), RIPK2 (NX_O43353), SGK1 (NX_O00141), STK11 (NX_Q15831), SYK (NX_P43405) and ZAP70 (NX_P43403). The proteins were selected on the basis of having sufficient literature to allow proper evaluation of the system, i.e. \>100 papers in a PubMed search, while avoiding the gene normalization problem, i.e. the gene name is not used as a synonym for another gene or as an acronym for a term used elsewhere in the literature. Example of proteins we avoided includes BTK (used in orthopedic papers as an acronym for 'below the knee') and ABL1 (used for ABL1 and ABL2 in older literature). The latter could have been controlled using the date range, while the former can be handled by excluding the word 'knee'. Having a certain number of different targets ensure that we cover a wide range of biological research areas, to increase the number of distinct concepts reported in the literature. This was aimed to control for biases, for example in the concept extraction step (as certain concepts have labels that are more difficult to extract by automated tools) and in the gene name extraction step (certain genes may have an abnormally high rate of false positives or false negatives, for example if a synonym is shared with another gene name or a concept or if the main gene name is not widely used in the literature).

Moreover, we ensured that each abstract was reviewed by two different curators, so as to have a measure of confidence of the evaluation of the annotations proposed by the automatic system, the rational being that when two curators do not agree, an error by neXtA~5~ should be less penalized.

###### 

Semantic classification of concepts annotated by the curators or proposed by neXtA~5~

  **Semantic classification**                 **GO terms**
  ------------------------------------------- ----------------------------------------------
  1                                           Reactive oxygen species biosynthetic process
  Reactive oxygen species metabolic process   
  ROS generation                              
  2                                           S phase
  DNA replication                             
  Regulation of cell cycle                    
  3                                           Autophagy
  Autophagosome assembly                      
  Autophagosome formation                     

Setting the baseline: inter-curator agreement {#sec9}
---------------------------------------------

Since curation is a subjective process to some extent, before comparing neXtA~5~'s performance as evaluated by curators, we determined the agreement between different curators for the tasks we evaluated for neXtA~5~.

### Strategy for assessing agreement with respect to concept extraction {#sec10}

Since the BP branch of the GO has nearly 30 000 classes, the selection of 2 different terms by 2 curators does not automatically imply a disagreement. The evaluation must take into account how related two terms are to decide whether two curators (or a curator and the automatic system) recognized a similar concept or not. To do this, we manually reviewed all annotated concepts (both by curators and by neXtA~5~) for all abstracts and manually assigned each concept to a semantic class, numbered from 1 to *n* for each abstract. This is illustrated in [Table 2](#TB3){ref-type="table"}. In this example, curators identified 9 different GO terms, which we classified into three semantic classes, labeled 1, 2 and 3. Concepts falling in the same semantic class were considered equivalent in our evaluation.

Here, we have decided to use a manually semantic classification approach rather than using the hierarchical structure in the GO. While the hierarchy of the GO could be used for this purposes (as in cases 1 and 3 in [Table 2](#TB3){ref-type="table"}), in other cases GO terms that represent the same experiment correspond to completely different areas of the tree, as shown in case 2 [Table 2](#TB3){ref-type="table"}. We have grouped the three GO terms S phase (GO:0051320), DNA replication (GO:0006260) and regulation of cell cycle (GO:0051726) into the same semantic classification group by manual classification, whereas these concepts belong to three different branches of the GO, as shown in [Figure 4](#f4){ref-type="fig"}.

![Ancestor charts of the GO terms from semantic classification 2, shown in [Table 2](#TB3){ref-type="table"} \[S phase (GO:0051320), DNA replication (GO:0006260) and regulation of cell cycle (GO:0051726)\], using <https://www.ebi.ac.uk/QuickGO/>.](bay129f4){#f4}

### (i) Inter-curator agreement test for precision of document retrieval {#sec11}

We first evaluated the inter-curator agreement with respect to the relevance of abstracts proposed by neXtA~5~, the so-called literature triage task. For this task, we determined the fraction of the first top-ranking 20 papers proposed by neXtA~5~ that were deemed relevant by both curators (assessed by whether or not they had identified relevant concepts in the abstract). The criteria for selecting an abstract as relevant for annotation were that it had information indicating that there was data in the full text paper relevant to the axis of interest. To exclude papers with general statements (rather than actual data), we specified the following guidelines: exclude statements from titles and from the introductory part of the abstract (highlighted in [Figure 5](#f5){ref-type="fig"}); and do not capture any 'hypothesis' type information, such as 'We hypothesized that the protein X performs process Y.' Examples of such sentences include 'Since activation of Ras oncogenes is a common oncogenic event leading to the activation of multiple effector pathways, we explored if Ras could induce Fyn expression.' ([@ref33]); 'The fact that IRAK4, another IRAK family member necessary for the IL-1 pathway, is able to phosphorylate IRAK in vitro suggests that IRAK4 might be the IRAK kinase.' ([@ref34]); 'The mechanism of activation for IRAK4 is currently unknown, and little is known about the role of IRAK4 kinase in cytokine production, particularly in different human cell types.' ([@ref35]); 'In this study, we analyzed the relative PTPN22 and CSK expression in peripheral blood from 89 RA patients and 43 controls to determine if the most relevant PTPN22 (rs2488457, rs2476601 and rs33996649) and CSK (rs34933034 and rs1378942) polymorphisms may influence on PTPN22 and CSK expression in rheumatoid arthritis (RA).' ([@ref36]).

![neXtA~5~ user interface for curation. One of the guidelines for the curators to select relevant documents was to not consider statements from titles and from the introductory part of the abstract. Here, the introduction of the abstract of ([@ref37]) related to FYN function (BP axis) is highlighted in yellow.](bay129f5){#f5}

Of the 12 proteins, a total of 242 abstracts were analyzed for each axis (for 12 targets, we expected to analyze 240 abstracts; however, in some cases abstracts with the same score were presented in a different order, which led to the annotation of 2 additional abstracts). As shown in [Table 3](#TB4){ref-type="table"}, in 83% of cases for BP and in 80% of cases for D, both curators made the same decision with respect to the relevance of an abstract for the axis of interest.

###### 

Inter-curator agreement analysis

                                        **BPs**   **Ds**              
  ------------------------------------- --------- --------- --------- ---------
  Papers accepted by both curators      162       **67%**   152       **63%**
  Papers rejected by both curators      39        **16%**   48        **17%**
  Papers rejected by just one curator   41        **17%**   42        **20%**
  Total papers analyzed                 **242**             **242**   

### (ii) Inter-curator agreement test for precision of concept retrieval {#sec12}

The precision of concept retrieval corresponds to the number of relevant terms extracted in each document. We assessed this by determining the rate at which both curators extracted the same concepts from an abstract. Again, specific curation guidelines were given: when similar descriptors are proposed, use the most accurate one, i.e. choose preferentially the child term than the parent term (for example, reject the annotation suggesting 'Neoplasm' when 'Ovarian carcinoma' is also mentioned in another annotation); annotations describing techniques (such as 'immunohistochemistry') are acceptable as indication of experimental data in the full text paper; and annotations describing negative evidence are included as relevant for annotation. If a concept was modified from the original concept, it had to be within the same branch of the ontology.

For this task, 45 abstracts of the BP axis and 51 abstracts of the D axis were annotated by two curators with BP and D terms, respectively (while the expected number of annotated papers for this task is 48, the actual number varies because the papers chosen by different curators for annotation may differ). This corresponds to a minimum of four abstracts by curator and by protein, with a few additional abstracts to ensure that at least two curators reviewed each abstract (the additional abstracts correspond to cases where curators made different decisions with respect to the relevance of an abstract for an axis). For the 45 abstracts annotated for the BP axis by both curators, at least 1 common term was found in 42 abstracts (93% of abstracts, [Figure 6A](#f6){ref-type="fig"}). The overall average inter-curator agreement rate with respect to concepts, i.e. the average proportion of concepts annotated by both curators relative to all concepts found by either curator, was of 60%. For the D axis, out of the 51 abstracts annotated by both curators, the 2 curators found at least 1 common term in 48 abstracts (94% of abstracts; [Figure 6B](#f6){ref-type="fig"}). The overall average inter-curator agreement rate with respect to concepts was of 87%.

![Inter-curator agreement with respect to concepts in BP (A) and D (B) axes showing the proportion of common concepts found by both curators. The number indicated is the number of common concepts identified by both curators (0--4 for BP; 0--6 for Ds).](bay129f6){#f6}

Hence, the inter-curator agreement is \~80% with respect to relevance of abstracts, regardless of the axis ([Table 3](#TB4){ref-type="table"}), and curators find at least 1 common concept in over 90% of the abstracts ([Figure 6](#f6){ref-type="fig"}). On average, 60% of the concepts in an abstract were identified by both curators for BP and 87% for Ds. This may reflect the greater complexity of GO compared to D terminology, which likely hampers annotation consistency.

neXtA~5~ evaluation {#sec13}
-------------------

We then evaluated the precision and the recall of the neXtA~5~ system. We evaluated the precision both at the level of the document retrieval and information extraction and the recall (as compared) with the manually extracted terms (as the set of expected true positives).

### (i) neXtA~5~ precision for document retrieval {#sec14}

Using the data from task (i) for inter-curator agreement, we can derive the fraction of the abstracts retrieved by neXtA~5~ and that curators assessed as relevant for the axis of interest. We find that both curators agree with neXtA~5~ for 67% of the abstracts suggested in the BP axis and for 63% of the abstracts in the D axis. Moreover, for 15% of the abstracts, both curators judged that the abstract was not relevant for the axis of interest ([Table 3](#TB4){ref-type="table"}).

### (ii) neXtA~5~ precision for information extraction {#sec15}

To determine the fraction of relevant concepts that neXtA~5~ retrieved, we manually evaluated each of the annotations proposed by neXtA~5~ for the 20 first abstracts, for each of the 12 target proteins (in cases where all concepts were rejected, additional abstracts were annotated until we reached 20 evaluated abstracts). Again, each abstract was evaluated independently by 2 curators, for a total of 254 abstracts. From these 254 abstracts, a total of 3175 annotations were proposed by the neXtA~5~ system. For the BP axis, curators approved or modified the proposed descriptor (a modification is a change of term within the same branch of the GO) for 35% of the terms; hence, 65% of the descriptors were considered as non-relevant. For the D axis, curators approved or modified the proposed descriptors for 25% of the cases and rejected 75% of the descriptors ([Table 4](#TB5){ref-type="table"}).

###### 

Precision analysis for BP and D axes

       **Total number of descriptors analyzed**   **Accepted**     **Modified**    **Rejected**     **Precision**
  ---- ------------------------------------------ ---------------- --------------- ---------------- ---------------
  BP   3175                                       699 **(22%)**    413 **(13%)**   2061 **(65%)**   **35%**
  Ds   4967                                       1094 **(22%)**   146 **(3%)**    3727 **(75%)**   **25%**

###### 

Average number of terms found by curators (common terms and total terms) and by neXtA~5~ for BP and D axes

                                                                     **BPs**   **Ds**
  ------------------------------------------------------------------ --------- --------
  Number of concepts identified by at least one curator and neXtA5   1.1       1.2
  Manual curator (average number of concepts/papers)                 2.4       1.5
  neXtA5 (average number of concepts/papers)                         6.2       6.0

neXtA~5~ recall for annotations {#sec16}
-------------------------------

To assess recall, curators manually extracted descriptors (independent of the neXtA~5~ information extraction module) from the first 4 abstracts for each of the 12 target proteins, as described in task (ii). Again, two curators performed the task for each abstract. We evaluated neXtA~5~ with two different criteria: (i) based on the descriptors only identified by both curators or (ii) based on the descriptors identified by either curator. That latest assessment is the best evaluation for an automated system; if a descriptor is identified manually, regardless of whether this assignment may be disputable, we don't expect an automatic system to be capable of such nuanced judgement.

For the BP axis, neXtA~5~ successfully identified 27% of the descriptors found by both curators and 36% of the terms identified by either curator ([Supplementary Data Table 1](https://academic.oup.com/database/article-lookup/doi/10.1093/database/bay129#supplementary-data)). For the D axis, neXtA~5~ identified 42% of the terms found by both curators and 68% of the terms identified by either curator.

Discussion {#sec17}
==========

Improvement of the manual annotation {#sec18}
------------------------------------

Our results show an inter-annotator agreement (IAA) of \~80% with respect to relevance of abstracts, regardless of the axis ([Table 3](#TB4){ref-type="table"}), and curators found at least 1 common concept in over 90% of the abstracts ([Figure 6](#f6){ref-type="fig"}). There is little data in the literature where inter-curator agreement was evaluated, so it is difficult to judge whether this is expected. A recent study, showing the mining of clinical attributes of genomic variants using Egas, a web-based platform for text-mining-assisted literature curation, presented an overall IAA of 74% ([@ref13]), while 2 other studies investigating the text-mining assisted biocuration workflows in Argo exhibited an IAA of 68.12% or varying between 67% and 84% ([@ref9], [@ref10]). Looking at some events of divergent decisions by the two curators, it seems that in most cases there was a drift from the curation guidelines and that if we return to the guidelines we can more often agree on the decision.

Performance of neXtA~5~ {#sec19}
-----------------------

We have developed neXtA~5~, a system that enhances the biocuration workflow by prioritizing research articles for specific tasks, and evaluated its performance with respect to document triage, precision and recall compared with manual annotation. These parameters are essential to develop a tool that can be used in the daily workflow of curated biological databases. We evaluated the effectiveness of the system to support the curation of GO BPs and Ds.

With respect to document retrieval, neXtA~5~ proposes \~15% of documents that are not relevant for the task at hand. This is quite acceptable, given that neXtProt curators routinely use PubMed to retrieve literature, which returns a much higher fraction of non-relevant documents, because it does not allow to specify a general domain of interest but only keywords. Moreover, this 15% is also similar to the rate at which curators disagree with each other with respect to the relevance of a document (17--20%; [Table 3](#TB4){ref-type="table"}), thus suggesting that the current triage effectiveness is approaching a theoretical upper bound.

For the concept extraction task, neXtA~5~ had a precision rate of 35% for BP and 25% for D and a recall rate of 27% for BP and 42% for D. It must be noted that neXtA~5~ retrieves 2.6 times more descriptors compared to curators in the BP axis ([Table 5](#TB6){ref-type="table"}). Indeed, neXtA~5~ finds an average of 6.2 concepts per abstract for the 45 abstracts annotated by both curators for the recall test, while curators find 2.4 terms and 1.1 common terms on average. In the D axis, neXtA~5~ finds an average of 6 concepts per abstract for the 45 abstracts annotated by both curators, while curators find 1.5 terms and 1.2 common terms on average. Therefore, neXtA~5~ finds four times more concepts than curators for the D axis. This high level of identified descriptors contributes to the low precision rate of neXtA~5~.

While the precision and recall performance do not yet allow for completely automated annotation, the fraction of relevant terms certainly makes the system a valuable enhancement to manual curation tasks.

Potential improvements of neXtA~5~ {#sec20}
==================================

While doing the evaluations, and based on their extensive experience in annotation, we noticed some recurring issues that should be addressed to enhance the performance of neXtA~5~.

Heterogeneity of neXtA~5~ concept extraction by annotation target {#sec21}
-----------------------------------------------------------------

We noticed significant heterogeneity in the precision of concept extraction among the different targets. For instance, in the BP axis, only 17% of the terms proposed for ZAP70 by neXtA~5~ were accepted or modified by the curators compared to 49% of the terms proposed for LRRK2 ([Table 6](#TB7){ref-type="table"}).

###### 

Precision analysis for BP (A) and D (B) axes

  **A**   **BPs**             **B**   **Ds**         
  ------- --------- --------- ------- -------- ----- ---------
  LRRK2   247       **49%**           LYN      398   **41%**
  SGK1    301       **43%**           SYK      570   **36%**
  SYK     262       **40%**           ZAP70    250   **31%**
  IRAK4   236       **39%**           PIM1     444   **30%**
  LYN     265       **38%**           FYN      402   **23%**
  FYN     343       **36%**           RIPK2    194   **23%**
  PIM1    327       **35%**           IRAK4    351   **22%**
  CDK2    333       **33%**           CDK2     504   **21%**
  RIPK2   145       **32%**           LRRK2    452   **19%**
  CSK     318       **29%**           SGK1     491   **19%**
  STK11   156       **27%**           STK11    635   **18%**
  ZAP70   242       **17%**           CSK      276   **18%**

This discrepancy might be due to synonyms that cause problems (formation, growth etc.), terms that are too vague (signaling, signal transduction, signaling cascade, regulation, carcinogenesis, tumor, autoimmune D etc.), technical terms (RNA interference, RNAi, knockout mice etc.) or non-relevant terms for the axis of interest (pathogenesis, memory, methylation, phosphorylation, localization, point mutations, gene variant, accumulation, sensitivity etc.; [Table 7](#TB8){ref-type="table"}).

###### 

List of rejected terms by the curators in BP (A) and D (B) axes

  [Table 7A](#TB8){ref-type="table"} List of rejected terms by the curator in biological process axis                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------- -------------- -------------- -------------- ----------- ---- --------- -----
  GO:0023052                                                                                            Signaling                                                   Signaling                                154            **56%**        63             **23%**     56   **21%**   273
  GO:0032502                                                                                            Developmental process                                       Developmental process                    112            **86%**        13             **10%**     5    **4%**    130
  GO:0065007                                                                                            N/A                                                         Biological regulation                    110            **81%**        26             **19%**     0    **0%**    136
  GO:0016310                                                                                            Phosphorylation                                             Phosphorylation                          110            **48%**        55             **24%**     66   **29%**   231
  GO:0007165                                                                                            Signal transduction                                         Signal transduction                      90             **76%**        11             **9%**      17   **14%**   118
  GO:0006351                                                                                            Transcription and DNA-templated                             Transcription and DNA-templated          88             **79%**        6              **5%**      18   **16%**   112
  GO:0009058                                                                                            Biosynthetic process                                        Biosynthetic process                     83             **80%**        19             **18%**     2    **2%**    104
  GO:0040007                                                                                            Growth                                                      Growth                                   74             **80%**        16             **17%**     2    **2%**    92
  GO:0010467                                                                                            Gene expression                                             Gene expression                          55             **76%**        1              **1%**      16   **22%**   72
  GO:0006915                                                                                            Apoptotic process                                           Apoptotic process                        44             **52%**        4              **5%**      36   **43%**   84
  GO:0009405                                                                                            N/A                                                         Pathogenesis                             42             **100%**       0              **0%**      0    **0%**    42
  GO:0051726                                                                                            Regulation of cell cycle                                    Regulation of cell cycle                 40             **82%**        2              **4%**      7    **14%**   49
  GO:0007049                                                                                            Cell cycle                                                  Cell cycle                               37             **65%**        4              **7%**      16   **28%**   57
  GO:0006954                                                                                            Inflammatory response                                       Inflammatory response                    36             **62%**        2              **3%**      20   **34%**   58
  GO:0006283                                                                                            Transcription-coupled nucleotide-excision repair            TCR                                      34             **77%**        9              **20%**     1    **2%**    44
  GO:0016246                                                                                            N/A                                                         RNA interference                         31             **100%**       0              **0%**      0    **0%**    31
  GO:0008283                                                                                            Cell proliferation                                          Cell proliferation                       31             **60%**        1              **2%**      20   **38%**   52
  GO:0009056                                                                                            Catabolic process                                           Catabolic process                        26             **59%**        10             **23%**     8    **18%**   44
  GO:0033673                                                                                            N/A                                                         Negative regulation of kinase activity   26             **100%**       0              **0%**      0    **0%**    26
  GO:0051179                                                                                            Localization                                                Localization                             24             **69%**        10             **29%**     1    **3%**    35
  GO:0008152                                                                                            Metabolic process                                           Metabolic process                        22             **88%**        0              **0%**      3    **12%**   25
  GO:0016049                                                                                            Cell growth                                                 Cell growth                              21             **81%**        1              **4%**      4    **15%**   26
  GO:0045087                                                                                            Innate immune response                                      Innate immune response                   19             **76%**        0              **0%**      6    **24%**   25
  GO:0001816                                                                                            Cytokine production                                         Cytokine production                      17             **52%**        1              **3%**      15   **45%**   33
  GO:0008219                                                                                            Cell death                                                  Cell death                               16             **57%**        2              **7%**      10   **36%**   28
  GO:0006412                                                                                            Translation                                                 Translation                              16             **53%**        1              **3%**      13   **43%**   30
  GO:0042110                                                                                            T cell activation                                           T-cell activation                        14             **70%**        0              **0%**      6    **30%**   20
  GO:0051320                                                                                            S phase                                                     S phase                                  13             **46%**        5              **18%**     10   **36%**   28
  GO:0046903                                                                                            Secretion                                                   Secretion                                13             **50%**        7              **27%**     6    **23%**   26
  GO:0006914                                                                                            Autophagy                                                   Autophagy                                13             **65%**        0              **0%**      7    **35%**   20
  GO:0030154                                                                                            Cell differentiation                                        Cell differentiation                     12             **86%**        2              **14%**     0    **0%**    14
  GO:0032259                                                                                            N/A                                                         Methylation                              12             **100%**       0              **0%**      0    **0%**    12
  GO:0006260                                                                                            DNA replication                                             DNA replication                          11             **55%**        0              **0%**      9    **45%**   20
  GO:0009293                                                                                            N/A                                                         Transduction                             11             **79%**        3              **21%**     0    **0%**    14
  GO:0006810                                                                                            N/A                                                         Transport                                11             **100%**       0              **0%**      0    **0%**    11
  GO:0046960                                                                                            Sensitization                                               Sensitization                            11             **92%**        0              **0%**      1    **8%**    12
  GO:0016311                                                                                            N/A                                                         Dephosphorylation                        10             **100%**       0              **0%**      0    **0%**    10
                                                                                                                                                                                                                                                                                     
  [Table 7B](#TB8){ref-type="table"} (Ds) List of rejected terms by the curator in disease axis                                                                                                                                                                                      
  **Unique concept**                                                                                    **Proposed concept**                                        **Proposed synonym**                     **Rejected**   **Modified**   **Accepted**   **Total**                  
  C2991                                                                                                 D or Disorder                                               Condition                                148            **89%**        11             **7%**      8    **5%**    167
  C3262                                                                                                 Neoplasm                                                    Tumor                                    100            **66%**        12             **8%**      39   **26%**   151
  C45576                                                                                                N/A                                                         Mutation                                 90             **100%**       0              **0%**      0    **0%**    90
  C9305                                                                                                 Malignant neoplasm                                          Cancer                                   90             **74%**        2              **2%**      29   **24%**   121
  C3114                                                                                                 Hypersensitivity                                            Sensitivity                              50             **94%**        1              **2%**      2    **4%**    53
  C3137                                                                                                 Inflammation                                                Inflammation                             49             **73%**        1              **1%**      17   **25%**   67
  C18264                                                                                                Pathogenesis                                                Pathogenesis                             46             **96%**        1              **2%**      1    **2%**    48
  C120860                                                                                               N/A                                                         Accumulation                             43             **100%**       0              **0%**      0    **0%**    43
  C18078                                                                                                Carcinogenesis                                              Tumorigenesis                            36             **71%**        4              **8%**      11   **22%**   51
  C26845                                                                                                Parkinson's D                                               Parkinson's D                            33             **79%**        0              **0%**      9    **21%**   42
  C19296                                                                                                N/A                                                         Deletion                                 32             **100%**       0              **0%**      0    **0%**    32
  C50753                                                                                                N/A                                                         Staining                                 30             **100%**       0              **0%**      0    **0%**    30
  C3324                                                                                                 Peutz--Jeghers syndrome                                     Peutz--Jeghers syndrome                  29             **83%**        0              **0%**      6    **17%**   35
  C14339                                                                                                N/A                                                         Knockout mice                            27             **100%**       0              **0%**      0    **0%**    27
  C20200                                                                                                N/A                                                         Outcome                                  26             **100%**       0              **0%**      0    **0%**    26
  C45581                                                                                                Gene amplification abnormality                              Amplification                            26             **96%**        0              **0%**      1    **4%**    27
  C3671                                                                                                 N/A                                                         Injury                                   25             **86%**        4              **14%**     0    **0%**    29
  C53802                                                                                                Adverse event associated with the gastrointestinal system   Gastrointestinal                         25             **83%**        0              **0%**      5    **17%**   30
  C42077                                                                                                Cellular infiltrate                                         Infiltration                             24             **89%**        0              **0%**      3    **11%**   27
  C17666                                                                                                N/A                                                         Germline mutations                       23             **100%**       0              **0%**      0    **0%**    23
  C75004                                                                                                Invasion                                                    Invasion                                 22             **79%**        1              **4%**      5    **18%**   28
  C55998                                                                                                N/A                                                         Platelets                                19             **100%**       0              **0%**      0    **0%**    19
  C3161                                                                                                 Leukemia                                                    Leukemia                                 19             **79%**        0              **0%**      5    **21%**   24
  C53791                                                                                                Adverse event associated with infection                     Infection                                18             **51%**        14             **40%**     3    **9%**    35
  C54685                                                                                                Tissue adhesion                                             Adhesion                                 17             **94%**        0              **0%**      1    **6%**    18
  C94604                                                                                                N/A                                                         Mouse model                              16             **100%**       0              **0%**      0    **0%**    16
  C39723                                                                                                Immune system finding                                       Immune system                            16             **94%**        0              **0%**      1    **6%**    17
  C19987                                                                                                Cancer progression                                          Cancer progression                       16             **89%**        0              **0%**      2    **11%**   18
  C4089                                                                                                 Polyposis                                                   Polyposis                                16             **89%**        1              **6%**      1    **6%**    18
  C93210                                                                                                Inflammatory disorder                                       Inflammatory Ds                          16             **76%**        0              **0%**      5    **24%**   21
  C19151                                                                                                Metastasis                                                  Metastases                               16             **36%**        5              **11%**     24   **53%**   45
  C53809                                                                                                Adverse event associated with the vascular system           Vascular                                 15             **88%**        0              **0%**      2    **12%**   17
  C17609                                                                                                Tumor progression                                           Tumor progression                        15             **83%**        0              **0%**      3    **17%**   18
  C3208                                                                                                 Lymphoma                                                    Lymphoma                                 15             **68%**        0              **0%**      7    **32%**   22
  C16897                                                                                                N/A                                                         Necrosis                                 14             **100%**       0              **0%**      0    **0%**    14
  C27990                                                                                                Toxicity                                                    Toxicity                                 14             **93%**        0              **0%**      1    **7%**    15
  C36117                                                                                                Invasive lesion                                             Invasive                                 14             **70%**        2              **10%**     4    **20%**   20
  C62200                                                                                                N/A                                                         Point mutation                           13             **100%**       0              **0%**      0    **0%**    13
  C39725                                                                                                Immunodeficiency                                            Immunodeficient                          13             **93%**        0              **0%**      1    **7%**    14
  C120867                                                                                               N/A                                                         Bacteria                                 13             **72%**        5              **28%**     0    **0%**    18
  C102283                                                                                               N/A                                                         Extracted                                12             **100%**       0              **0%**      0    **0%**    12
  C17354                                                                                                N/A                                                         Frameshift mutation                      12             **100%**       0              **0%**      0    **0%**    12
  C28193                                                                                                N/A                                                         Syndrome                                 12             **100%**       0              **0%**      0    **0%**    12
  C2873                                                                                                 N/A                                                         Aneuploidy                               12             **100%**       0              **0%**      0    **0%**    12
  C45582                                                                                                N/A                                                         Duplication                              12             **100%**       0              **0%**      0    **0%**    12
  C18016                                                                                                Loss of heterozygosity                                      Allelic loss                             12             **92%**        0              **0%**      1    **8%**    13
  C14174                                                                                                N/A                                                         Metastatic                               12             **86%**        2              **14%**     0    **0%**    14
  C50774                                                                                                Tissue degeneration                                         Degeneration                             12             **86%**        0              **0%**      2    **14%**   14
  C2916                                                                                                 Carcinoma                                                   Carcinomas                               12             **80%**        2              **13%**     1    **7%**    15
  C3340                                                                                                 Polyp                                                       Polyps                                   12             **75%**        1              **6%**      3    **19%**   16
  C2950                                                                                                 Cytogenetic abnormality                                     Chromosomal aberration                   11             **92%**        0              **0%**      1    **8%**    12
  C3117                                                                                                 Hypertension                                                Hypertension                             11             **73%**        0              **0%**      4    **27%**   15
  C4872                                                                                                 Breast carcinoma                                            Breast carcinomas                        11             **39%**        0              **0%**      17   **61%**   28
  C120945                                                                                               N/A                                                         Inclusions                               10             **100%**       0              **0%**      0    **0%**    10
  C17212                                                                                                N/A                                                         Cell transformation                      10             **100%**       0              **0%**      0    **0%**    10
  C18133                                                                                                N/A                                                         Missense mutations                       10             **100%**       0              **0%**      0    **0%**    10
  C3101                                                                                                 N/A                                                         Inherited D                              10             **100%**       0              **0%**      0    **0%**    10
  C3174                                                                                                 N/A                                                         Chronic myelogenous leukemia             10             **100%**       0              **0%**      0    **0%**    10
  C48189                                                                                                N/A                                                         Genome instability                       10             **100%**       0              **0%**      0    **0%**    10
  C48275                                                                                                N/A                                                         Fatal                                    10             **100%**       0              **0%**      0    **0%**    10
  C8509                                                                                                 Primary neoplasm                                            Primary tumor                            10             **71%**        0              **0%**      4    **29%**   14

Terms always rejected are highlighted in grey. The list is limited to terms proposed at least 30 times by the system. The proposed label does not necessarily correspond to the primary class label; it may be the term synonym identified by neXtA~5~.

A few concepts considered by the annotators (\~4%) were chosen from terms not indexed by the name entity recognition module. This minor inconsistency from the input may have contributed to some discrepancy in the results between the manual and neXtA~5~ annotations.

Highly rejected terms {#sec22}
---------------------

We have also noticed for both axes that certain terms are frequently rejected, while others are always rejected (highlighted terms; [Table 7](#TB8){ref-type="table"}, [Supplementary Data Table 2](https://academic.oup.com/database/article-lookup/doi/10.1093/database/bay129#supplementary-data)). Those include synonyms with multiple semantic meanings (formation, growth etc.), terms that are too vague (signaling, signal transduction, regulation, developmental process, carcinogenesis, tumor, autoimmune D, genome instability, outcome etc.), technical terms (RNA interference, RNAi, knockout mice, staining etc.) or non-relevant terms for the axis of interest (such as pathogenesis, memory, methylation, phosphorylation, dephosphorylation, localization, point mutation, accumulation, sensitivity etc.). One possible approach to alleviate this problem would be to put these terms on a black list and not propose them as annotations. Ideally, those terms would also be excluded from the prioritization step, which would also have the advantage of improving the triage step.

Improvements to the user interface {#sec23}
----------------------------------

In addition to improving the document triage and concept extraction algorithms, the users have noticed several improvements to the user interface that would facilitate the workflow.

In the current neXtA~5~ user interface, annotations are displayed according to the position of the descriptor in the text. This was one of the initial specifications of the project, to improve readability and allow curators to know exactly where concepts were extracted from the text. However, while neXtA~5~ is able to suggest relevant descriptors, those descriptors are spread over many irrelevant or trivial descriptors. After performing the usability study, we realized that being able to rank the evidences could deliver a complementary view. In the current GUI, the two types of views are available and the default remains the linear view, which seems somehow more intuitive. We do consider that such complementary revisions are somehow expected as outcome of usability studies.

It would therefore be much more efficient from an interaction point of view to display annotations based on their estimated relevance. We have experimented with improvement to the ranking function of the specific axes. The impact on the performance resulting from these changes in the ranking function seems promising. This additional assessment was performed using TREC_EVAL tool ([@ref38]), and the results relate the relevance of the annotations proposed by the system at top ranks (P0 for the precision at first rank and P5 for the precision on the five first descriptors returned).

For GO BP, we used a machine-learning approach to improve the ranking of the annotations displayed by neXtA~5~. We used GOCat, a large multiclass multilabel categorizer ([@ref39]), that exploits more than 100 000 curated citations from the Gene Ontology Annotation (GOA) database (<https://www.ebi.ac.uk/GOA/downloads>) and aims at inferring GO annotations for any textual input (abstracts, sentences etc.) it receives. As GOCat learns from GOA, the proposed GO concepts are modeling a manual curation task. The GOCat system showed highly competitive results during the BioCreative 2014 competition, which explored a GO automatic annotation task ([@ref40]). In neXtA~5~, GOCat output is used to promote GO descriptors identified in the input text. Thanks to GOCat, neXtA~5~ improves performances from 0.48 to 0.63 in P0 (+31%) and from 0.28 to 0.35 for P5 (+25%) ([Table 8](#TB9){ref-type="table"}).

###### 

Results of learning to rank applied to annotations

            **Baseline**   **Re-ranking**            
  --------- -------------- ---------------- -------- --------
            **P0**         **P5**           **P0**   **P5**
  **BPs**   0.48           0.28             0.63     0.35
  **Ds**    0.48           0.17             0.59     0.22

For Ds, we used a simple TF--IDF scoring function to estimate the importance of every single annotation. The basic assumption is that important concepts from the curator perspective tend to occur repeatedly in the corpus of texts (i.e. the meaningful entities detected by neXtA~5~ would be repeated through the abstracts). However, these high-frequency concepts may also be regular English words; therefore, the raw frequency of occurrence must be balanced by the inverse document frequency, i.e. the frequency of the concept in a large sample of MEDLINE. As presented in the [Table 8](#TB9){ref-type="table"}, this simple approach results in a significant precision gain of +23% at first rank.

Perspective {#sec24}
===========

Our results show that the neXtA~5~ system performs well enough to improve the manual curation workflow. The average consensus between curators covers 60% of the concepts for the BPs and 87% for the Ds. neXtA~5~ is then intended to reach similar performance, and prior experiments already show that the exclusion of specific terms and the re-ranking of annotations highly impact on its precision without negatively impacting the recall.

From abstracts to full-text articles {#sec25}
------------------------------------

neXtA~5~ was developed and optimized using abstracts. The analysis of full-text articles is necessary for this tool to be usable in a production setting. Full-text papers pose many problems ([@ref3]), most are only available in pdf format that should be Optical character recognition (ORC) preprocessed and some are not even available due to the journal access policy. Certain sections, most notably the introduction and the discussion, have a lower interest for the curation, respectively due to the type of information and to the redundancy. For these reasons, the abstract is probably the most useful part of a research article to perform article prioritization. This is not the case for concept extraction; the neXtProt curators (as well as most other curated databases) extract data directly based on experimental results, so it is mandatory that the full text of the paper be reviewed. One middle-way solution would be to allow curators to paste text in a form, which would then be used for concept extraction from neXtA~5~. This would avoid the problem of automatic recognition of article's sections that is notoriously difficult ([@ref41]) while making use of the strengths of the system to recognize concepts.

Perspectives for neXtA~5~ {#sec26}
-------------------------

The results of this study convinced us that neXtA~5~ is a valuable addition to our curation pipeline, and we are in the process of implementing neXtA~5~ in the BioEditor curation tool. We are now considering the customization of the curation-support platform to support other use cases of other manually curated resources, such as the detection of positional information (post-translational modifications and variants). These use cases focus more heavily on triage that is both the most mature component of the platform and the most needed service for professional curators. Further developments are ongoing to apply the system to a wider range of curated databases, including core resources of Elixir (<https://www.elixir-europe.org/>) such as DisProt ([@ref42]), that will require developing text-mining services to recognize lesser studied entities such as sequence positions. The annotation services will also be expanded to support the annotation of full-text contents. Indeed, while triage is performed mostly on abstracts, the authoring of curated annotations does require the use of full-text contents.

Finally, we are committed to develop neXtA~5~ according to state-of-the-art methodologies. Our work ([@ref29]) and that of other groups ([@ref43]) indicate that machine-learning assisted triage method could improve the document retrieval process, outperforming manual curators at least for specific tasks. As machine learning does better than other strategies only in cases where the available body of data is sufficiently large, this approach is currently limited to few data types. We will continue to explore all appropriate algorithms for our use cases and adjust our algorithms as new development occurs that could justify changes in strategies.

Software availability {#sec27}
=====================

A demo version of neXtA~5~ is available at <http://candy.hesge.ch/nextA5>. The manual judgements on which this study is based are included in [Table 3](#TB4){ref-type="table"}.
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======================
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